| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Itgal |
| Uniprot No | P20701 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 150-336aa |
| 氨基酸序列 | CIKGNVDLVFLFDGSMSLQPDEFQKILDFMKDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYVATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLHKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEG |
| 预测分子量 | 50.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITGAL(整合素αL)重组蛋白的模拟参考文献示例：
---
1. **文献名称**：*Expression and functional characterization of recombinant human integrin αLβ2 (LFA-1) in mammalian cells*
**作者**：Smith A, et al.
**摘要**：本研究利用HEK293细胞成功表达并纯化功能性重组人ITGAL/β2(LFA-1)蛋白，证实其在体外介导淋巴细胞与ICAM-1的结合，为免疫互作研究提供工具。
2. **文献名称**：*Structural insights into ITGAL activation mechanism by cryo-EM*
**作者**：Zhang Y, et al.
**摘要**：通过冷冻电镜解析重组ITGAL/β2的活化态结构，揭示其构象变化如何调控与ICAM-1的结合，为抗炎药物设计提供结构基础。
3. **文献名称**：*ITGAL recombinant protein as a therapeutic target in autoimmune disease models*
**作者**：Brown K, et al.
**摘要**：评估重组ITGAL蛋白阻断剂在类风湿性关节炎模型中的疗效，证明其可抑制白细胞浸润并减轻炎症，提示临床转化潜力。
---
**注**：以上文献为示例性内容，实际引用时请通过学术数据库(如PubMed、Web of Science)核实真实文献。
**Background of ITGAL (Integrin Alpha L) Recombinant Protein**
Integrin alpha L (ITGAL), also known as CD11a, is a key subunit of the heterodimeric integrin receptor LFA-1 (lymphocyte function-associated antigen-1), which pairs with the beta-2 subunit (CD18) to form a critical cell adhesion molecule. LFA-1 is predominantly expressed on leukocytes and plays a central role in mediating immune cell interactions, including lymphocyte homing, T-cell activation, and leukocyte migration to sites of inflammation. ITGAL facilitates these processes by binding to intercellular adhesion molecules (ICAMs) on endothelial and antigen-presenting cells, enabling immune surveillance and inflammatory responses.
Recombinant ITGAL protein is engineered using biotechnological platforms, such as mammalian or insect cell expression systems, to ensure proper post-translational modifications and functional fidelity. This recombinant form retains the extracellular domain responsible for ligand binding, making it a valuable tool for studying LFA-1/ICAM interactions in vitro. Researchers utilize ITGAL recombinant proteins to investigate immune cell adhesion mechanisms, screen for therapeutic inhibitors targeting inflammatory diseases (e.g., autoimmune disorders), or develop diagnostic assays.
The therapeutic relevance of ITGAL is underscored by its involvement in pathologies like rheumatoid arthritis, multiple sclerosis, and transplant rejection. Blocking LFA-1 signaling has emerged as a strategy to modulate excessive immune activation, with drugs like lifitegrast (approved for dry eye disease) exemplifying clinical applications. Additionally, recombinant ITGAL aids in structural studies to map binding epitopes and optimize drug design.
In summary, ITGAL recombinant protein serves as a pivotal resource in immunology and drug discovery, bridging mechanistic insights into leukocyte biology with translational innovations for immune-related diseases.
×
